Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Earnings Data
Report Date
Apr 23, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.43Last Year’s EPS
10.04Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and financial story driven by Sephience's rapid global approvals and impressive early launch metrics, revenue outperformance for 2025, a strengthened cash position (~$1.95B), disciplined OpEx, and clear R&D progress (notably votoplam Phase III alignment). Offsetting items include regulatory setbacks for vatiquinone requiring additional study, reduced future Evrysdi royalty exposure following a royalty sale, pressure on the DMD franchise from generics, and some near-term expense increases and geographic concentration of Sephience revenue. Overall, the positives (robust launch, revenue beat, cash runway, and advancing pipeline programs) materially outweigh the negatives, though several development and commercialization risks remain.Company Guidance
Successful Global Sephience Approvals and Launch
Sephience gained approvals in the U.S., EU, Japan and other countries in 2025 and launched globally with strong early uptake. Q4 2025 Sephience revenue was $92M (U.S. $81M, ex-U.S. $11M) and Sephience generated $111M worldwide since launch in 2025. As of Dec 31, 2025 there were 946 patients on commercial therapy and 1,134 patient start forms in the U.S.; >80% of U.S. PKU centers of excellence have prescribed Sephience.
Overall Revenue Outperformance
Full year 2025 total net product and royalty revenue was $831M, exceeding guidance of $750M–$800M (surpassing the upper bound by $31M). Q4 2025 total net product and royalty revenue was $263M and full year product revenue was $587M.
Strong Financial Position and Liquidity
Cash, cash equivalents and marketable securities were $1.95B as of Dec 31, 2025, up from $1.14B a year earlier (≈+71% year-over-year), bolstered by disciplined OpEx and monetization activities.
Disciplined Operating Expense Management
Non-GAAP combined R&D and SG&A OpEx for 2025 was $728M, which came in below the prior guidance range of $730M–$760M, demonstrating operational discipline.
Evrysdi Royalty Monetization
PTC sold the remainder of its Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M in sales-based milestones while retaining the right to a $150M Roche milestone tied to single-year Evrysdi sales of $2.5B, providing near-term liquidity.
2026 Growth Guidance and Path to Cash-Flow Breakeven
2026 product revenue guidance is $700M–$800M, representing 19%–36% product revenue growth versus 2025 (2025 product revenue $587M). Expense guidance for 2026 is $680M–$720M (non-GAAP R&D + SG&A), and the company expects potential to reach cash-flow breakeven in 2026.
Progress Across R&D Portfolio — Votoplam and Other Programs
Positive Phase II PIVOT-HD results for votoplam; FDA end-of-Phase-II alignment reached on Phase III INVEST-HD design. Novartis will initiate INVEST-HD in H1 2026 (target ~770 participants, 3:2 randomization, planned interim efficacy/futility analysis). Additional programs advancing: RNA splicing candidates, MSH3 development candidate election, NLRP3 Phase I initiation by mid-2026, and progression of ferroptosis/NRF2 programs.
Favorable Payer and Real-World Dynamics for Sephience
Payers have generally supported open Sephience access (few barriers, limited/no step edits, refills up to 12 months). High refill rates and low single-digit discontinuation rates reported; social media and patient advocacy driving awareness and demand, including re-engagement of 'lost to follow-up' adults.
PTCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PTCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $69.90 | $70.66 | +1.09% |
Nov 04, 2025 | $67.72 | $71.77 | +5.98% |
Aug 07, 2025 | $50.36 | $45.38 | -9.89% |
May 06, 2025 | $36.19 | $40.76 | +12.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PTC Therapeutics (PTCT) report earnings?
PTC Therapeutics (PTCT) is schdueled to report earning on Apr 23, 2026, After Close (Confirmed).
What is PTC Therapeutics (PTCT) earnings time?
PTC Therapeutics (PTCT) earnings time is at Apr 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTCT EPS forecast?
PTCT EPS forecast for the fiscal quarter 2026 (Q1) is -0.43.